Occurrence of pharmaceuticals and endocrine disrupting compounds in Brazilian water and the risks they may represent to human health.

Registro completo de metadados
MetadadosDescriçãoIdioma
Autor(es): dc.creatorAquino, Sergio Francisco de-
Autor(es): dc.creatorBrandt, Emanuel Manfred Freire-
Autor(es): dc.creatorBottrel, Sue Ellen Costa-
Autor(es): dc.creatorGomes, Fernanda Bento Rosa-
Autor(es): dc.creatorSilva, Silvana de Queiroz-
Data de aceite: dc.date.accessioned2025-08-21T15:55:26Z-
Data de disponibilização: dc.date.available2025-08-21T15:55:26Z-
Data de envio: dc.date.issued2023-05-24-
Data de envio: dc.date.issued2023-05-24-
Data de envio: dc.date.issued2020-
Fonte completa do material: dc.identifierhttp://www.repositorio.ufop.br/jspui/handle/123456789/16662-
Fonte completa do material: dc.identifierhttps://doi.org/10.3390/ijerph182211765-
Fonte: dc.identifier.urihttp://educapes.capes.gov.br/handle/capes/1027576-
Descrição: dc.descriptionThe risks of pharmaceuticals and endocrine disrupting compounds (P&EDC) to the en- vironment and human health are a current topic of interest. Hundreds of P&EDC may reach the environment, hence, there is a need to rank the level of concern of human exposure to these com- pounds. Thus, this work aimed at setting a priority list of P&EDC in Brazil, by studying their occurrence in raw and drinking water, calculating health guideline values (GV), and estimating the risks of population exposure to water intake. Data on the Brazilian pharmaceutical market as well as published data of the monitoring of Brazilian natural and drinking water have been collected by means of an exhaustive literature review. Furthermore, many foreign data were also collected to enable a comparison of the values found in Brazilian studies. A list of 55 P&EDC that have the potential to be found in Brazilian water is proposed, and for 41 of these a risk assessment was performed by estimating their margin of exposure (ME), by considering their occurrence in drinking water, and guideline values estimated from reported acceptable daily intake (ADI) data. For seven compounds the risk was deemed high (three estrogens and four anti-inflammatories), whereas for another seven compounds, it was regarded as an ‘alert’ situation. Although such risk analysis is conservative, since it has been calculated based on the highest reported P&EDC concentration in drinking water, it highlights the need to enhance their monitoring in Brazil to strengthen the database and support decision makers. An analysis of the occurrence of antimicrobial resistance agents (antibiotics, resistant bacteria, and resistance genes) in surface waters was also carried out and confirmed that such agents are present in water sources throughout Brazil, which deserves the attention of policy makers and health agents to prevent dissemination of antimicrobial resistance through water use.-
Formato: dc.formatapplication/pdf-
Idioma: dc.languageen-
Direitos: dc.rightsaberto-
Direitos: dc.rightsThis article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/ 4.0/). Fonte: o PDF do artigo.-
Palavras-chave: dc.subjectAntibiotics-
Palavras-chave: dc.subjectDrinking water-
Palavras-chave: dc.subjectContaminants of emerging concern-
Palavras-chave: dc.subjectHormones-
Palavras-chave: dc.subjectAntimicrobial resistance-
Título: dc.titleOccurrence of pharmaceuticals and endocrine disrupting compounds in Brazilian water and the risks they may represent to human health.-
Aparece nas coleções:Repositório Institucional - UFOP

Não existem arquivos associados a este item.